

Best in the Microworld. Better beyond the Globe



# MEDITRANS



Advancing Healthcare Together

**EverFlow<sup>®</sup>**

Paclitaxel Coated PTCA Balloon Catheter

**Efficient Drug Delivery  
and Proven Efficacy**

*Promise for Heart*

**MEDITRANS**  Contact Info



Jakarta : Jl Munggang no. 86-87 Balekambang  
Kramat Jati, Jakarta Timur, 13530  
Surabaya : Rungkut Menanggal Harapan  
Blok O No. 28, Surabaya 60293  
Others : Bandung, Makassar, Medan, Balikpapan



(+62) 21 2204 7248  
(+62) 31 8786 2593  
(+62) 821 8000 1102



[www.meditrans.id](http://www.meditrans.id)



[info@meditrans.id](mailto:info@meditrans.id)



[meditrans.id](https://www.facebook.com/meditrans.id)




[meditransid](https://www.instagram.com/meditransid)




## EverFlow® Design Features

The system comprise of drug delivery specific balloon catheter (VesTraveler®) and polymer-free paclitaxel drug coating.



- ★ **Drug Delivery Specific Balloon Catheter (VesTraveler®):** designed specifically for drug and stent delivery with features of semi-compliant, excellent crossability and precision balloon expansion
- ★ **Special HighBind® Coating Technology:** Uniformly 100% surface coating, precision drug loading and controlled drug release profile
- ★ **Evidence-driven of Medicine:** minimum drug loss during delivery and controlled release profile during balloon expansion
- ★ **Proven Long-last vessel drug retention and efficacy:** effective drug dose remain in vessel up to 30days post balloon expansion.



**EverFlow® Paclitaxel Coated PTCA Balloon Catheter**

**Drug Delivery Specific Balloon Catheter**

**Uniformly 100% Balloon Surface Coating**

**Controlled Drug Release:**  
•Better drug Adhesion  
•High Drug Transfer to Vessel





**Precision Drug Loading**

**Proven Long-Last Vessel Drug Retention & Efficacy**

**Balloon Expanded**




**Evidence-Driven Device Safety and Efficacy**



**QCA and Histomorphometric comparison between SeQuent & EverFlow in porcine coronary arteries 90days post expansion:** there are no significant different. (LA: lumen Area; IEA: internal Elastic Area; MA: Media Area; NIA: Neointima Area; RFD: vessel reference diameter; MLD: minimal lumen diameter; Lumen loss(%DS)=LLL/MLD post x 100%.(Inside Data).



# Evidence-Driven Device Safety and Efficacy



**Coronary Vessel Paclitaxel Residual Dosage:** Sufficient and remain up to 35 days post balloon expansion ( Paclitaxel safe & efficacy concentration: 0.0085–0.85ug/ml. Axel et al: Circulation. 1997; 96:636–645; Sollot et al; J. Clin.Invest. 1995; 95: 1869–1876 )

EverFlow® PTX Pharmacokinetics Study (PK)						
Tissues		Time Points(ug/g)				
		0	1 h	24 h	7 days	35 days
Blood		2.62*	0.0084±0.0043 (n=8)	0	0	0
Vessels (Balloon Injured)		/	6.04±1.78 (n=4)	3.64±2.21 (n=5)	0.024±.0082 (n=3)	0.0043±0.0018 (n=3)
Core Life Organs	Myocardium		0.21	0.006	0	0
	Liver		0	0	0	0
	Spleen		0	0	0	0
	Lung		0	0	0.0091	0
	Kidney		0	0	0	0
	Brain		0	0	0	0

**EverFlow® PK Data:** Paclitaxel (PTX) was detected only within one week in the core organs post balloon expansion, and within safe range (Inside data).



# Order Information

EverFlow® Paclitaxel-Coated PTCA Balloon Catheter (sizes)									
Balloon Diameter (mm)	Balloon Length (mm)								
	10	14	18	22	26	30	34	38	
2.00	2.00X10	2.00X14	2.00X18	2.00X22	2.00X26	2.00X30	2.00X34	2.00X38	
2.25	2.25X10	2.25X14	2.25X18	2.25X22	2.25X26	2.25X30	2.25X34	2.25X38	
2.50	2.50X10	2.50X14	2.50X18	2.50X22	2.50X26	2.50X30	2.50X34	2.50X38	
2.75	2.75X10	2.75X14	2.75X18	2.75X22	2.75X26	2.75X30	2.75X34	2.75X38	
3.00	3.00X10	3.00X14	3.00X18	3.00X22	3.00X26	3.00X30	3.00X34	3.00X38	
3.25	3.25X10	3.25X14	3.25X18	3.25X22	3.25X26	3.25X30	3.25X34	3.25X38	
3.50	3.50X10	3.50X14	3.50X18	3.50X22	3.50X26	3.50X30	3.50X34	3.50X38	
3.75	3.75X10	3.75X14	3.75X18	3.75X22	3.75X26	3.75X30	3.75X34	3.75X38	
4.00	4.00X10	4.00X14	4.00X18	4.00X22	4.00X26	4.00X30	4.00X34	4.00X38	

**CAUTION:** The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

EverFlow® is a trademark or registered trademark of TT Medical. All cited trademarks are the property of their respective owners.



**EverFlow® Indications:**

- ◆ De novo lesions (primary use in the case of stenosis or occlusion) including small vessels (SVD)
- ◆ Residual stenosis after balloon or stent PTCA
- ◆ Pre and post dilatation during coronary stent implantation
- ◆ Acute or impending vascular occlusion

**Instruction for Use:**

Material required to perform a PTCA balloon catheter procedure:

- ◆ Rapid Exchange PTCA catheter
- ◆ Guiding catheter
- ◆ Inflation syringe with gauge
- ◆ Introduction lock set with dilator
- ◆ 0.014 inch × 175 cm guide wire
- ◆ Contrast medium
- ◆ Y–connector with haemostatic adapter

Prior to use, it is essential that all the instruments, catheters and individual components are carefully checked. An integrity test of the balloon (with the protective balloon sheath left in place), a complete removal of air from the system and a thorough control of the connector seals are mandatory.

Detail description for Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device